News
Sales of the ground-breaking cystic fibrosis (CF) drug Kaftrio was the main driver behind revenues of a Dublin unit of Vertex ...
7h
Zacks Investment Research on MSNCRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?CRISPR Therapeutics CRSP and Intellia Therapeutics NTLA are leading developers of therapies that utilize the Nobel ...
Analysts remain bullish on Vertex Pharmaceuticals as HC Wainwright reaffirmed its buy rating with a $550 price target.
Researchers at Vertex Pharmaceuticals in Boston say a single infusion of stem cell-based treatment could be a permanent ...
This was the stock's second consecutive day of gains.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now. On June 20, Vertex ...
TUESDAY, June 24, 2025 (HealthDay News) — A single infusion of a new stem cell-based treatment may have helped 10 out of 12 ...
A study may have found a cure for type 1 diabetes. Here, experts explain how the treatment, zimislecel, works and what it ...
Vertex Pharmaceuticals locked arms with Ono Pharmaceutical in an exclusive deal to advance povetacicept, targeting B ...
CHICAGO -- Mifepristone (Korlym) reduced HbA1c levels in patients with inadequately controlled type 2 diabetes and ...
"This edition of the Healthcare Enforcement column discusses two judicial decisions from recent months relating to the ...
Sickle Cell Disease Treatment Market Trends, Growth Forecast & Top Players 2025 | DataM Intelligence
The Sickle Cell Disease Treatment Market is expected to reach at a CAGR of 15.8% during the forecast period 2025-2033. The Sickle Cell Disease Treatment Market is growing due to rising disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results